Selected research
Market Outlook & Growth Opportunities
Global Gene Therapy on Neurological Diseases Market Outlook and Growth Opportunities 2026
Market perspective
The global Gene Therapy on Neurological Diseases market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.
The North America market for Gene Therapy on Neurological Diseases is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Gene Therapy on Neurological Diseases is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Gene Therapy on Neurological Diseases is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
In China, the Gene Therapy on Neurological Diseases market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Major global companies in the Gene Therapy on Neurological Diseases market include Novartis, Biogen and Sarepta Therapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.
This report provides an overview of the global Gene Therapy on Neurological Diseases market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Gene Therapy on Neurological Diseases and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Gene Therapy on Neurological Diseases revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Gene Therapy on Neurological Diseases market.
Gene Therapy on Neurological Diseases Segment by Company
Novartis
Biogen
Sarepta Therapeutics
Gene Therapy on Neurological Diseases Segment by Type
Viral Gene Therapy
Non-viral Gene Therapy
Gene Therapy on Neurological Diseases Segment by Application
Hospital
Clinic
Other
Gene Therapy on Neurological Diseases Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Gene Therapy on Neurological Diseases status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Gene Therapy on Neurological Diseases key companies, revenue, market share, and recent developments.
3. To split the Gene Therapy on Neurological Diseases breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Gene Therapy on Neurological Diseases market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Gene Therapy on Neurological Diseases significant trends, drivers, influence factors in global and regions.
6. To analyze Gene Therapy on Neurological Diseases competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gene Therapy on Neurological Diseases market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Gene Therapy on Neurological Diseases and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gene Therapy on Neurological Diseases.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Gene Therapy on Neurological Diseases industry.
Chapter 3: Detailed analysis of Gene Therapy on Neurological Diseases company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Gene Therapy on Neurological Diseases in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Gene Therapy on Neurological Diseases in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
More report detail
Tables and figures
List of Tables
Table 1. Gene Therapy on Neurological Diseases Industry Trends
Table 2. Gene Therapy on Neurological Diseases Industry Drivers
Table 3. Gene Therapy on Neurological Diseases Industry Opportunities and Challenges
Table 4. Gene Therapy on Neurological Diseases Industry Restraints
Table 5. Global Gene Therapy on Neurological Diseases Revenue by Company (US$ Million) & (2021-2026)
Table 6. Global Gene Therapy on Neurological Diseases Revenue Share by Company (2021-2026)
Table 7. Global Gene Therapy on Neurological Diseases Company Ranking, (2024-2026) & (US$ Million)
Table 8. Global Gene Therapy on Neurological Diseases Key Company Manufacturing Base & Headquarters
Table 9. Global Gene Therapy on Neurological Diseases Company, Product Type & Application
Table 10. Global Gene Therapy on Neurological Diseases Company Establishment Date
Table 11. Global Company Market Concentration Ratio (CR5 and HHI)
Table 12. Global Gene Therapy on Neurological Diseases by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025)
Table 13. Mergers & Acquisitions, Expansion
Table 14. Significant Companies of Viral Gene Therapy
Table 15. Significant Companies of Non-viral Gene Therapy
Table 16. Global Gene Therapy on Neurological Diseases Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million)
Table 17. Global Gene Therapy on Neurological Diseases Sales Value by Type (2021-2026) & (US$ Million)
Table 18. Global Gene Therapy on Neurological Diseases Sales Value by Type (2027-2032) & (US$ Million)
Table 19. Global Gene Therapy on Neurological Diseases Sales Value Share by Type (2021-2026)
Table 20. Global Gene Therapy on Neurological Diseases Sales Value Share by Type (2027-2032)
Table 21. Significant Companies of Hospital
Table 22. Significant Companies of Clinic
Table 23. Significant Companies of Other
Table 24. Global Gene Therapy on Neurological Diseases Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million)
Table 25. Global Gene Therapy on Neurological Diseases Sales Value by Application (2021-2026) & (US$ Million)
Table 26. Global Gene Therapy on Neurological Diseases Sales Value by Application (2027-2032) & (US$ Million)
Table 27. Global Gene Therapy on Neurological Diseases Sales Value Share by Application (2021-2026)
Table 28. Global Gene Therapy on Neurological Diseases Sales Value Share by Application (2027-2032)
Table 29. Global Gene Therapy on Neurological Diseases Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million)
Table 30. Global Gene Therapy on Neurological Diseases Sales Value by Region (2021-2026) & (US$ Million)
Table 31. Global Gene Therapy on Neurological Diseases Sales Value Share by Region (2021-2026)
Table 32. Global Gene Therapy on Neurological Diseases Sales Value by Region (2027-2032) & (US$ Million)
Table 33. Global Gene Therapy on Neurological Diseases Sales Value Share by Region (2027-2032)
Table 34. Global Gene Therapy on Neurological Diseases Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 35. Global Gene Therapy on Neurological Diseases Sales Value by Country (2021-2026) & (US$ Million)
Table 36. Global Gene Therapy on Neurological Diseases Sales Value Market Share by Country (2021-2026)
Table 37. Global Gene Therapy on Neurological Diseases Sales Value by Country (2027-2032) & (US$ Million)
Table 38. Global Gene Therapy on Neurological Diseases Sales Value Market Share by Country (2027-2032)
Table 39. Novartis Company Information
Table 40. Novartis Business Overview
Table 41. Novartis Gene Therapy on Neurological Diseases Revenue (US$ Million) and Gross Margin (2021-2026)
Table 42. Novartis Gene Therapy on Neurological Diseases Product Portfolio
Table 43. Novartis Recent Development
Table 44. Biogen Company Information
Table 45. Biogen Business Overview
Table 46. Biogen Gene Therapy on Neurological Diseases Revenue (US$ Million) and Gross Margin (2021-2026)
Table 47. Biogen Gene Therapy on Neurological Diseases Product Portfolio
Table 48. Biogen Recent Development
Table 49. Sarepta Therapeutics Company Information
Table 50. Sarepta Therapeutics Business Overview
Table 51. Sarepta Therapeutics Gene Therapy on Neurological Diseases Revenue (US$ Million) and Gross Margin (2021-2026)
Table 52. Sarepta Therapeutics Gene Therapy on Neurological Diseases Product Portfolio
Table 53. Sarepta Therapeutics Recent Development
Table 54. Research Programs/Design for This Report
Table 55. Authors List of This Report
Table 56. Secondary Sources
Table 57. Primary Sources
List of Figures
Figure 1. Gene Therapy on Neurological Diseases Product Image
Figure 2. Global Gene Therapy on Neurological Diseases Market Size (US$ Million), 2021 VS 2025 VS 2032
Figure 3. Global Gene Therapy on Neurological Diseases Market Size (2021-2032) & (US$ Million)
Figure 4. Global Gene Therapy on Neurological Diseases Company Revenue Ranking in 2025 (US$ Million)
Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million)
Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 7. Viral Gene Therapy Image
Figure 8. Non-viral Gene Therapy Image
Figure 9. Global Gene Therapy on Neurological Diseases Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million)
Figure 10. Global Gene Therapy on Neurological Diseases Sales Value Share 2021 VS 2025 VS 2032
Figure 11. Global Gene Therapy on Neurological Diseases Sales Value Share by Type (2021-2032)
Figure 12. Hospital Image
Figure 13. Clinic Image
Figure 14. Other Image
Figure 15. Global Gene Therapy on Neurological Diseases Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million)
Figure 16. Global Gene Therapy on Neurological Diseases Sales Value Share 2021 VS 2025 VS 2032
Figure 17. Global Gene Therapy on Neurological Diseases Sales Value Share by Application (2021-2032)
Figure 18. Global Gene Therapy on Neurological Diseases Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million)
Figure 19. Global Gene Therapy on Neurological Diseases Sales Value Share by Region: 2021 VS 2025 VS 2032
Figure 20. North America Gene Therapy on Neurological Diseases Sales Value (2021-2032) & (US$ Million)
Figure 21. North America Gene Therapy on Neurological Diseases Sales Value Share by Country (%), 2025 VS 2032
Figure 22. Europe Gene Therapy on Neurological Diseases Sales Value (2021-2032) & (US$ Million)
Figure 23. Europe Gene Therapy on Neurological Diseases Sales Value Share by Country (%), 2025 VS 2032
Figure 24. Asia-Pacific Gene Therapy on Neurological Diseases Sales Value (2021-2032) & (US$ Million)
Figure 25. Asia-Pacific Gene Therapy on Neurological Diseases Sales Value Share by Country (%), 2025 VS 2032
Figure 26. South America Gene Therapy on Neurological Diseases Sales Value (2021-2032) & (US$ Million)
Figure 27. South America Gene Therapy on Neurological Diseases Sales Value Share by Country (%), 2025 VS 2032
Figure 28. Middle East & Africa Gene Therapy on Neurological Diseases Sales Value (2021-2032) & (US$ Million)
Figure 29. Middle East & Africa Gene Therapy on Neurological Diseases Sales Value Share by Country (%), 2025 VS 2032
Figure 30. USA Gene Therapy on Neurological Diseases Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 31. USA Gene Therapy on Neurological Diseases Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 32. USA Gene Therapy on Neurological Diseases Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 33. Canada Gene Therapy on Neurological Diseases Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 34. Canada Gene Therapy on Neurological Diseases Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 35. Canada Gene Therapy on Neurological Diseases Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 36. Mexico Gene Therapy on Neurological Diseases Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 37. Mexico Gene Therapy on Neurological Diseases Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 38. Mexico Gene Therapy on Neurological Diseases Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 39. Germany Gene Therapy on Neurological Diseases Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 40. Germany Gene Therapy on Neurological Diseases Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 41. Germany Gene Therapy on Neurological Diseases Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 42. France Gene Therapy on Neurological Diseases Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 43. France Gene Therapy on Neurological Diseases Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 44. France Gene Therapy on Neurological Diseases Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 45. U.K. Gene Therapy on Neurological Diseases Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 46. U.K. Gene Therapy on Neurological Diseases Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 47. U.K. Gene Therapy on Neurological Diseases Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 48. Italy Gene Therapy on Neurological Diseases Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 49. Italy Gene Therapy on Neurological Diseases Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 50. Italy Gene Therapy on Neurological Diseases Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 51. Spain Gene Therapy on Neurological Diseases Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 52. Spain Gene Therapy on Neurological Diseases Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 53. Spain Gene Therapy on Neurological Diseases Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 54. Russia Gene Therapy on Neurological Diseases Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 55. Russia Gene Therapy on Neurological Diseases Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 56. Russia Gene Therapy on Neurological Diseases Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 57. Netherlands Gene Therapy on Neurological Diseases Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 58. Netherlands Gene Therapy on Neurological Diseases Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 59. Netherlands Gene Therapy on Neurological Diseases Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 60. Nordic Countries Gene Therapy on Neurological Diseases Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 61. Nordic Countries Gene Therapy on Neurological Diseases Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 62. Nordic Countries Gene Therapy on Neurological Diseases Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 63. China Gene Therapy on Neurological Diseases Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 64. China Gene Therapy on Neurological Diseases Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 65. China Gene Therapy on Neurological Diseases Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 66. Japan Gene Therapy on Neurological Diseases Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 67. Japan Gene Therapy on Neurological Diseases Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 68. Japan Gene Therapy on Neurological Diseases Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 69. South Korea Gene Therapy on Neurological Diseases Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 70. South Korea Gene Therapy on Neurological Diseases Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 71. South Korea Gene Therapy on Neurological Diseases Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 72. India Gene Therapy on Neurological Diseases Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 73. India Gene Therapy on Neurological Diseases Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 74. India Gene Therapy on Neurological Diseases Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 75. Australia Gene Therapy on Neurological Diseases Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 76. Australia Gene Therapy on Neurological Diseases Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 77. Australia Gene Therapy on Neurological Diseases Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 78. Southeast Asia Gene Therapy on Neurological Diseases Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 79. Southeast Asia Gene Therapy on Neurological Diseases Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 80. Southeast Asia Gene Therapy on Neurological Diseases Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 81. Brazil Gene Therapy on Neurological Diseases Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 82. Brazil Gene Therapy on Neurological Diseases Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 83. Brazil Gene Therapy on Neurological Diseases Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 84. Argentina Gene Therapy on Neurological Diseases Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 85. Argentina Gene Therapy on Neurological Diseases Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 86. Argentina Gene Therapy on Neurological Diseases Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 87. Chile Gene Therapy on Neurological Diseases Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 88. Chile Gene Therapy on Neurological Diseases Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 89. Chile Gene Therapy on Neurological Diseases Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 90. Colombia Gene Therapy on Neurological Diseases Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 91. Colombia Gene Therapy on Neurological Diseases Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 92. Colombia Gene Therapy on Neurological Diseases Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 93. Peru Gene Therapy on Neurological Diseases Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 94. Peru Gene Therapy on Neurological Diseases Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 95. Peru Gene Therapy on Neurological Diseases Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 96. Saudi Arabia Gene Therapy on Neurological Diseases Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 97. Saudi Arabia Gene Therapy on Neurological Diseases Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 98. Saudi Arabia Gene Therapy on Neurological Diseases Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 99. Israel Gene Therapy on Neurological Diseases Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 100. Israel Gene Therapy on Neurological Diseases Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 101. Israel Gene Therapy on Neurological Diseases Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 102. UAE Gene Therapy on Neurological Diseases Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 103. UAE Gene Therapy on Neurological Diseases Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 104. UAE Gene Therapy on Neurological Diseases Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 105. Turkey Gene Therapy on Neurological Diseases Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 106. Turkey Gene Therapy on Neurological Diseases Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 107. Turkey Gene Therapy on Neurological Diseases Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 108. Iran Gene Therapy on Neurological Diseases Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 109. Iran Gene Therapy on Neurological Diseases Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 110. Iran Gene Therapy on Neurological Diseases Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 111. Egypt Gene Therapy on Neurological Diseases Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 112. Egypt Gene Therapy on Neurological Diseases Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 113. Egypt Gene Therapy on Neurological Diseases Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 114. Years Considered
Figure 115. Research Process
Figure 116. Key Executives Interviewed
Scope & coverage.
Types
- Viral Gene Therapy
- Non-viral Gene Therapy
Applications
- Hospital
- Clinic
- Other
Companies covered
- Novartis
- Biogen
- Sarepta Therapeutics
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Gene Therapy on Neurological Diseases Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Gene Therapy on Neurological Diseases Market Size (2021-2032)
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Gene Therapy on Neurological Diseases Market Dynamics
- 2.1 Gene Therapy on Neurological Diseases Industry Trends
- 2.2 Gene Therapy on Neurological Diseases Industry Drivers
- 2.3 Gene Therapy on Neurological Diseases Industry Opportunities and Challenges
- 2.4 Gene Therapy on Neurological Diseases Industry Restraints
3 Gene Therapy on Neurological Diseases Market by Company
- 3.1 Global Gene Therapy on Neurological Diseases Company Revenue Ranking in 2025
- 3.2 Global Gene Therapy on Neurological Diseases Revenue by Company (2021-2026)
- 3.3 Global Gene Therapy on Neurological Diseases Company Ranking (2024-2026)
- 3.4 Global Gene Therapy on Neurological Diseases Company Manufacturing Base and Headquarters
- 3.5 Global Gene Therapy on Neurological Diseases Company Product Type and Application
- 3.6 Global Gene Therapy on Neurological Diseases Company Establishment Date
- 3.7 Market Competitive Analysis
- 3.7.1 Global Gene Therapy on Neurological Diseases Market Concentration Ratio (CR5 and HHI)
- 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
- 3.7.3 2025 Gene Therapy on Neurological Diseases Tier 1, Tier 2, and Tier 3 Companies
- 3.8 Mergers and Acquisitions Expansion
4 Gene Therapy on Neurological Diseases Market by Type
- 4.1 Gene Therapy on Neurological Diseases Type Introduction
- 4.1.1 Viral Gene Therapy
- 4.1.2 Non-viral Gene Therapy
- 4.2 Global Gene Therapy on Neurological Diseases Sales Value by Type
- 4.2.1 Global Gene Therapy on Neurological Diseases Sales Value by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Gene Therapy on Neurological Diseases Sales Value by Type (2021-2032)
- 4.2.3 Global Gene Therapy on Neurological Diseases Sales Value Share by Type (2021-2032)
5 Gene Therapy on Neurological Diseases Market by Application
- 5.1 Gene Therapy on Neurological Diseases Application Introduction
- 5.1.1 Hospital
- 5.1.2 Clinic
- 5.1.3 Other
- 5.2 Global Gene Therapy on Neurological Diseases Sales Value by Application
- 5.2.1 Global Gene Therapy on Neurological Diseases Sales Value by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Gene Therapy on Neurological Diseases Sales Value by Application (2021-2032)
- 5.2.3 Global Gene Therapy on Neurological Diseases Sales Value Share by Application (2021-2032)
6 Gene Therapy on Neurological Diseases Regional Value Analysis
- 6.1 Global Gene Therapy on Neurological Diseases Sales Value by Region: 2021 VS 2025 VS 2032
- 6.2 Global Gene Therapy on Neurological Diseases Sales Value by Region (2021-2032)
- 6.2.1 Global Gene Therapy on Neurological Diseases Sales Value by Region: 2021-2026
- 6.2.2 Global Gene Therapy on Neurological Diseases Sales Value by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Gene Therapy on Neurological Diseases Sales Value (2021-2032)
- 6.3.2 North America Gene Therapy on Neurological Diseases Sales Value Share by Country, 2025 VS 2032
- 6.4 Europe
- 6.4.1 Europe Gene Therapy on Neurological Diseases Sales Value (2021-2032)
- 6.4.2 Europe Gene Therapy on Neurological Diseases Sales Value Share by Country, 2025 VS 2032
- 6.5 Asia-Pacific
- 6.5.1 Asia-Pacific Gene Therapy on Neurological Diseases Sales Value (2021-2032)
- 6.5.2 Asia-Pacific Gene Therapy on Neurological Diseases Sales Value Share by Country, 2025 VS 2032
- 6.6 South America
- 6.6.1 South America Gene Therapy on Neurological Diseases Sales Value (2021-2032)
- 6.6.2 South America Gene Therapy on Neurological Diseases Sales Value Share by Country, 2025 VS 2032
- 6.7 Middle East & Africa
- 6.7.1 Middle East & Africa Gene Therapy on Neurological Diseases Sales Value (2021-2032)
- 6.7.2 Middle East & Africa Gene Therapy on Neurological Diseases Sales Value Share by Country, 2025 VS 2032
7 Gene Therapy on Neurological Diseases Country-level Value Analysis
- 7.1 Global Gene Therapy on Neurological Diseases Sales Value by Country: 2021 VS 2025 VS 2032
- 7.2 Global Gene Therapy on Neurological Diseases Sales Value by Country (2021-2032)
- 7.2.1 Global Gene Therapy on Neurological Diseases Sales Value by Country (2021-2026)
- 7.2.2 Global Gene Therapy on Neurological Diseases Sales Value by Country (2027-2032)
- 7.3 USA
- 7.3.1 USA Gene Therapy on Neurological Diseases Sales Value Growth Rate (2021-2032)
- 7.3.2 USA Gene Therapy on Neurological Diseases Sales Value Share by Type, 2025 VS 2032
- 7.3.3 USA Gene Therapy on Neurological Diseases Sales Value Share by Application, 2025 VS 2032
- 7.4 Canada
- 7.4.1 Canada Gene Therapy on Neurological Diseases Sales Value Growth Rate (2021-2032)
- 7.4.2 Canada Gene Therapy on Neurological Diseases Sales Value Share by Type, 2025 VS 2032
- 7.4.3 Canada Gene Therapy on Neurological Diseases Sales Value Share by Application, 2025 VS 2032
- 7.5 Mexico
- 7.5.1 Mexico Gene Therapy on Neurological Diseases Sales Value Growth Rate (2021-2032)
- 7.5.2 Mexico Gene Therapy on Neurological Diseases Sales Value Share by Type, 2025 VS 2032
- 7.5.3 Mexico Gene Therapy on Neurological Diseases Sales Value Share by Application, 2025 VS 2032
- 7.6 Germany
- 7.6.1 Germany Gene Therapy on Neurological Diseases Sales Value Growth Rate (2021-2032)
- 7.6.2 Germany Gene Therapy on Neurological Diseases Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Germany Gene Therapy on Neurological Diseases Sales Value Share by Application, 2025 VS 2032
- 7.7 France
- 7.7.1 France Gene Therapy on Neurological Diseases Sales Value Growth Rate (2021-2032)
- 7.7.2 France Gene Therapy on Neurological Diseases Sales Value Share by Type, 2025 VS 2032
- 7.7.3 France Gene Therapy on Neurological Diseases Sales Value Share by Application, 2025 VS 2032
- 7.8 U.K.
- 7.8.1 U.K. Gene Therapy on Neurological Diseases Sales Value Growth Rate (2021-2032)
- 7.8.2 U.K. Gene Therapy on Neurological Diseases Sales Value Share by Type, 2025 VS 2032
- 7.8.3 U.K. Gene Therapy on Neurological Diseases Sales Value Share by Application, 2025 VS 2032
- 7.9 Italy
- 7.9.1 Italy Gene Therapy on Neurological Diseases Sales Value Growth Rate (2021-2032)
- 7.9.2 Italy Gene Therapy on Neurological Diseases Sales Value Share by Type, 2025 VS 2032
- 7.9.3 Italy Gene Therapy on Neurological Diseases Sales Value Share by Application, 2025 VS 2032
- 7.10 Spain
- 7.10.1 Spain Gene Therapy on Neurological Diseases Sales Value Growth Rate (2021-2032)
- 7.10.2 Spain Gene Therapy on Neurological Diseases Sales Value Share by Type, 2025 VS 2032
- 7.10.3 Spain Gene Therapy on Neurological Diseases Sales Value Share by Application, 2025 VS 2032
- 7.11 Russia
- 7.11.1 Russia Gene Therapy on Neurological Diseases Sales Value Growth Rate (2021-2032)
- 7.11.2 Russia Gene Therapy on Neurological Diseases Sales Value Share by Type, 2025 VS 2032
- 7.11.3 Russia Gene Therapy on Neurological Diseases Sales Value Share by Application, 2025 VS 2032
- 7.12 Netherlands
- 7.12.1 Netherlands Gene Therapy on Neurological Diseases Sales Value Growth Rate (2021-2032)
- 7.12.2 Netherlands Gene Therapy on Neurological Diseases Sales Value Share by Type, 2025 VS 2032
- 7.12.3 Netherlands Gene Therapy on Neurological Diseases Sales Value Share by Application, 2025 VS 2032
- 7.13 Nordic Countries
- 7.13.1 Nordic Countries Gene Therapy on Neurological Diseases Sales Value Growth Rate (2021-2032)
- 7.13.2 Nordic Countries Gene Therapy on Neurological Diseases Sales Value Share by Type, 2025 VS 2032
- 7.13.3 Nordic Countries Gene Therapy on Neurological Diseases Sales Value Share by Application, 2025 VS 2032
- 7.14 China
- 7.14.1 China Gene Therapy on Neurological Diseases Sales Value Growth Rate (2021-2032)
- 7.14.2 China Gene Therapy on Neurological Diseases Sales Value Share by Type, 2025 VS 2032
- 7.14.3 China Gene Therapy on Neurological Diseases Sales Value Share by Application, 2025 VS 2032
- 7.15 Japan
- 7.15.1 Japan Gene Therapy on Neurological Diseases Sales Value Growth Rate (2021-2032)
- 7.15.2 Japan Gene Therapy on Neurological Diseases Sales Value Share by Type, 2025 VS 2032
- 7.15.3 Japan Gene Therapy on Neurological Diseases Sales Value Share by Application, 2025 VS 2032
- 7.16 South Korea
- 7.16.1 South Korea Gene Therapy on Neurological Diseases Sales Value Growth Rate (2021-2032)
- 7.16.2 South Korea Gene Therapy on Neurological Diseases Sales Value Share by Type, 2025 VS 2032
- 7.16.3 South Korea Gene Therapy on Neurological Diseases Sales Value Share by Application, 2025 VS 2032
- 7.17 India
- 7.17.1 India Gene Therapy on Neurological Diseases Sales Value Growth Rate (2021-2032)
- 7.17.2 India Gene Therapy on Neurological Diseases Sales Value Share by Type, 2025 VS 2032
- 7.17.3 India Gene Therapy on Neurological Diseases Sales Value Share by Application, 2025 VS 2032
- 7.18 Australia
- 7.18.1 Australia Gene Therapy on Neurological Diseases Sales Value Growth Rate (2021-2032)
- 7.18.2 Australia Gene Therapy on Neurological Diseases Sales Value Share by Type, 2025 VS 2032
- 7.18.3 Australia Gene Therapy on Neurological Diseases Sales Value Share by Application, 2025 VS 2032
- 7.19 Southeast Asia
- 7.19.1 Southeast Asia Gene Therapy on Neurological Diseases Sales Value Growth Rate (2021-2032)
- 7.19.2 Southeast Asia Gene Therapy on Neurological Diseases Sales Value Share by Type, 2025 VS 2032
- 7.19.3 Southeast Asia Gene Therapy on Neurological Diseases Sales Value Share by Application, 2025 VS 2032
- 7.20 Brazil
- 7.20.1 Brazil Gene Therapy on Neurological Diseases Sales Value Growth Rate (2021-2032)
- 7.20.2 Brazil Gene Therapy on Neurological Diseases Sales Value Share by Type, 2025 VS 2032
- 7.20.3 Brazil Gene Therapy on Neurological Diseases Sales Value Share by Application, 2025 VS 2032
- 7.21 Argentina
- 7.21.1 Argentina Gene Therapy on Neurological Diseases Sales Value Growth Rate (2021-2032)
- 7.21.2 Argentina Gene Therapy on Neurological Diseases Sales Value Share by Type, 2025 VS 2032
- 7.21.3 Argentina Gene Therapy on Neurological Diseases Sales Value Share by Application, 2025 VS 2032
- 7.22 Chile
- 7.22.1 Chile Gene Therapy on Neurological Diseases Sales Value Growth Rate (2021-2032)
- 7.22.2 Chile Gene Therapy on Neurological Diseases Sales Value Share by Type, 2025 VS 2032
- 7.22.3 Chile Gene Therapy on Neurological Diseases Sales Value Share by Application, 2025 VS 2032
- 7.23 Colombia
- 7.23.1 Colombia Gene Therapy on Neurological Diseases Sales Value Growth Rate (2021-2032)
- 7.23.2 Colombia Gene Therapy on Neurological Diseases Sales Value Share by Type, 2025 VS 2032
- 7.23.3 Colombia Gene Therapy on Neurological Diseases Sales Value Share by Application, 2025 VS 2032
- 7.24 Peru
- 7.24.1 Peru Gene Therapy on Neurological Diseases Sales Value Growth Rate (2021-2032)
- 7.24.2 Peru Gene Therapy on Neurological Diseases Sales Value Share by Type, 2025 VS 2032
- 7.24.3 Peru Gene Therapy on Neurological Diseases Sales Value Share by Application, 2025 VS 2032
- 7.25 Saudi Arabia
- 7.25.1 Saudi Arabia Gene Therapy on Neurological Diseases Sales Value Growth Rate (2021-2032)
- 7.25.2 Saudi Arabia Gene Therapy on Neurological Diseases Sales Value Share by Type, 2025 VS 2032
- 7.25.3 Saudi Arabia Gene Therapy on Neurological Diseases Sales Value Share by Application, 2025 VS 2032
- 7.26 Israel
- 7.26.1 Israel Gene Therapy on Neurological Diseases Sales Value Growth Rate (2021-2032)
- 7.26.2 Israel Gene Therapy on Neurological Diseases Sales Value Share by Type, 2025 VS 2032
- 7.26.3 Israel Gene Therapy on Neurological Diseases Sales Value Share by Application, 2025 VS 2032
- 7.27 UAE
- 7.27.1 UAE Gene Therapy on Neurological Diseases Sales Value Growth Rate (2021-2032)
- 7.27.2 UAE Gene Therapy on Neurological Diseases Sales Value Share by Type, 2025 VS 2032
- 7.27.3 UAE Gene Therapy on Neurological Diseases Sales Value Share by Application, 2025 VS 2032
- 7.28 Turkey
- 7.28.1 Turkey Gene Therapy on Neurological Diseases Sales Value Growth Rate (2021-2032)
- 7.28.2 Turkey Gene Therapy on Neurological Diseases Sales Value Share by Type, 2025 VS 2032
- 7.28.3 Turkey Gene Therapy on Neurological Diseases Sales Value Share by Application, 2025 VS 2032
- 7.29 Iran
- 7.29.1 Iran Gene Therapy on Neurological Diseases Sales Value Growth Rate (2021-2032)
- 7.29.2 Iran Gene Therapy on Neurological Diseases Sales Value Share by Type, 2025 VS 2032
- 7.29.3 Iran Gene Therapy on Neurological Diseases Sales Value Share by Application, 2025 VS 2032
- 7.30 Egypt
- 7.30.1 Egypt Gene Therapy on Neurological Diseases Sales Value Growth Rate (2021-2032)
- 7.30.2 Egypt Gene Therapy on Neurological Diseases Sales Value Share by Type, 2025 VS 2032
- 7.30.3 Egypt Gene Therapy on Neurological Diseases Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
- 8.1 Novartis
- 8.1.1 Novartis Company Information
- 8.1.2 Novartis Business Overview
- 8.1.3 Novartis Gene Therapy on Neurological Diseases Revenue and Gross Margin (2021-2026)
- 8.1.4 Novartis Gene Therapy on Neurological Diseases Product Portfolio
- 8.1.5 Novartis Recent Developments
- 8.2 Biogen
- 8.2.1 Biogen Company Information
- 8.2.2 Biogen Business Overview
- 8.2.3 Biogen Gene Therapy on Neurological Diseases Revenue and Gross Margin (2021-2026)
- 8.2.4 Biogen Gene Therapy on Neurological Diseases Product Portfolio
- 8.2.5 Biogen Recent Developments
- 8.3 Sarepta Therapeutics
- 8.3.1 Sarepta Therapeutics Company Information
- 8.3.2 Sarepta Therapeutics Business Overview
- 8.3.3 Sarepta Therapeutics Gene Therapy on Neurological Diseases Revenue and Gross Margin (2021-2026)
- 8.3.4 Sarepta Therapeutics Gene Therapy on Neurological Diseases Product Portfolio
- 8.3.5 Sarepta Therapeutics Recent Developments
9 Concluding Insights
10 Appendix
- 10.1 Reasons for Doing This Study
- 10.2 Research Methodology
- 10.3 Research Process
- 10.4 Authors List of This Report
- 10.5 Data Source
- 10.5.1 Secondary Sources
- 10.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
$4,250USD
Buy nowPDF by email within 3–5 working days after payment confirmation.
Talk to an analyst